Key terms

About A

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest A news

Mar 15 9:39am ET China stimulus positive for GE HealthCare, tool companies, says Evercore ISI Mar 01 12:55am ET Buy Rating Affirmed with Increased Price Target for Agilent Amidst Stabilizing Chinese Market and Strong Q1 Performance Feb 28 9:55am ET Early notable gainers among liquid option names on February 28th Feb 28 9:30am ET Agilent price target raised to $141 from $138 at BofA Feb 28 7:22am ET Agilent price target raised to $163 from $156 at TD Cowen Feb 28 7:02am ET Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Xencor (XNCR) Feb 28 6:51am ET Agilent price target raised to $143 from $138 at Baird Feb 28 6:33am ET A Earnings: Agilent Soars on Q1 Beat Feb 28 6:28am ET Agilent price target raised to $145 from $130 at Citi Feb 28 5:22am ET Agilent price target raised to $125 from $120 at Barclays Feb 28 3:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Ligand Pharma (LGND), Agilent (A) and Eli Lilly & Co (LLY) Feb 28 12:20am ET Analysts Offer Insights on Healthcare Companies: Raffles Medical Group (OtherRAFLF), Agilent (A) and Karuna Therapeutics (KRTX) Feb 27 4:31pm ET Agilent sees Q2 EPS $1.17-$1.20, consensus $1.27 Feb 27 4:30pm ET Agilent sees FY24 EPS $5.44-$5.55, consensus $5.49 Feb 27 4:29pm ET Agilent reports Q1 adjusted EPS $1.29, consensus $1.22 Feb 25 11:30pm ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 21 4:42pm ET Agilent Announces CEO Retirement and Successor Appointment Feb 21 4:12pm ET Agilent CEO Mike McMullen to retire Jan 31 2:56am ET Agilent Sell Rating: A Comprehensive Evaluation of Financials, Valuation, and Industry Trends Jan 30 8:11am ET Agilent, Incyte collaborate to develop advanced companion diagnostics Jan 24 7:18am ET Agilent price target raised to $120 from $100 at Barclays Dec 20 5:41pm ET Agilent moves Cell Analysis Division into DGG to strengthen growth opportunities

No recent news articles are available for A

No recent press releases are available for A

A Financials

1-year income & revenue

Key terms

A Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

A Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms